Analysts Set Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Target Price at $6.55

Shares of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) have been assigned a consensus recommendation of “Buy” from the five brokerages that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $6.55.

A number of brokerages have weighed in on SGTX. cut their price objective on shares of Sigilon Therapeutics from $12.00 to $7.00 and set a “buy” rating on the stock in a report on Thursday, December 23rd. BTIG Research restated a “buy” rating and issued a $14.00 price target on shares of Sigilon Therapeutics in a research note on Tuesday, November 30th. Jefferies Financial Group cut Sigilon Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $15.00 to $4.00 in a research note on Tuesday, November 30th. Zacks Investment Research raised Sigilon Therapeutics from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research report on Tuesday, December 21st. Finally, Morgan Stanley cut their price objective on shares of Sigilon Therapeutics from $9.00 to $4.50 and set an “equal weight” rating on the stock in a research report on Tuesday, November 30th.

Large investors have recently modified their holdings of the business. BlackRock Inc. lifted its holdings in shares of Sigilon Therapeutics by 24.0% during the 3rd quarter. BlackRock Inc. now owns 1,740,942 shares of the company’s stock valued at $9,837,000 after buying an additional 336,658 shares during the period. Morgan Stanley grew its stake in shares of Sigilon Therapeutics by 26,803.2% during the 2nd quarter. Morgan Stanley now owns 546,942 shares of the company’s stock valued at $5,869,000 after purchasing an additional 544,909 shares during the period. American Century Companies Inc. increased its position in shares of Sigilon Therapeutics by 10.7% during the 3rd quarter. American Century Companies Inc. now owns 359,688 shares of the company’s stock valued at $2,033,000 after purchasing an additional 34,806 shares during the last quarter. Monashee Investment Management LLC bought a new position in shares of Sigilon Therapeutics in the 2nd quarter worth approximately $3,406,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Sigilon Therapeutics by 73.2% in the third quarter. Geode Capital Management LLC now owns 231,662 shares of the company’s stock worth $1,308,000 after buying an additional 97,887 shares during the last quarter. 59.73% of the stock is owned by institutional investors and hedge funds.

SGTX opened at $2.20 on Wednesday. Sigilon Therapeutics has a one year low of $2.07 and a one year high of $45.00. The business has a 50 day simple moving average of $3.37 and a two-hundred day simple moving average of $5.23. The firm has a market capitalization of $71.08 million and a price-to-earnings ratio of -0.73.

Sigilon Therapeutics (NASDAQ:SGTX) last announced its quarterly earnings data on Wednesday, November 10th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.03. The firm had revenue of $1.95 million for the quarter, compared to analysts’ expectations of $3.20 million. On average, analysts anticipate that Sigilon Therapeutics will post -2.29 earnings per share for the current fiscal year.

About Sigilon Therapeutics

Sigilon Therapeutics, Inc, a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes.

Recommended Story: Is it better to buy a fund with a higher or lower NAV?

Receive News & Ratings for Sigilon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sigilon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.